A. Marcellin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Raltegravir (MK-0518) is clinically used against viruses resistant to other antiretroviral compounds. However, it has been reported that Raltegravir induces integrase (IN) resistance very soon after the administration of the drug. Some residues in the protein seem to be preferentially targeted: E92Q, N155H, and the double mutant G140S/ Q148H. It was(More)
  • 1